Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-05-18 Sale | 2026-05-20 4:16 pm | Replimune Group Inc. | REPL | Astley-Sparke Philip Director | 17,657 | $5.08 | $89,698 | 1,412,414 (Direct) | View |
| 2025-05-20 Sale | 2025-05-22 9:47 pm | Replimune Group Inc. | REPL | Astley-Sparke Philip Director | 32,279 | $8.06 | $260,169 | 1,405,071 (Direct) | View |
| 2024-05-16 Sale | 2024-05-20 8:04 pm | Replimune Group Inc. | REPL | Astley-Sparke Philip Executive Chairman | 37,928 | $6.47 | $245,394 | 1,487,350 (Direct) | View |
| 2023-05-16 Sale | 2023-05-18 8:30 pm | Replimune Group Inc. | REPL | Astley-Sparke Philip Chief Executive Officer | 17,902 | $18.05 | $323,131 | 1,525,278 (Direct) | View |
| 2022-05-16 Sale | 2022-05-18 7:00 pm | Replimune Group Inc. | REPL | Astley-Sparke Philip Chief Executive Officer | 9,632 | $14.59 | $140,531 | 1,401,080 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-06-16 Option Award | 2026-06-17 5:44 pm | N/A 2036-06-16 | enGene Therapeutics Inc. | ENGN | Astley-Sparke Philip Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2026-04-01 Option Award | 2026-04-07 9:10 pm | N/A 2036-04-01 | Replimune Group Inc. | REPL | Astley-Sparke Philip Director | 125,000 | $0 | 1,505,071 (Direct) | View |
| 2026-02-18 Gift | 2026-02-20 4:15 pm | N/A N/A | Replimune Group Inc. | REPL | Astley-Sparke Philip Director | 25,000 | $0 | 1,380,071 (Direct) | View |
| 2025-07-08 Option Award | 2025-07-10 4:07 pm | N/A 2035-07-08 | enGene Holdings Inc. | ENGN | Astley-Sparke Philip Director | 45,000 | $0 | 45,000 (Direct) | View |
Ownership | 2025-07-08 4:11 pm | N/A N/A | enGene Holdings Inc. | ENGN | Astley-Sparke Philip Director | 0 | $0 | 20,000 (Direct) | View |
| 2024-08-30 Gift | 2024-08-30 8:00 pm | N/A N/A | Replimune Group Inc. | REPL | Astley-Sparke Philip Executive Chairman | 50,000 | $0 | 1,437,350 (Direct) | View |
| 2023-04-01 Option Award | 2023-04-04 8:00 pm | N/A 2033-04-01 | Replimune Group Inc. | REPL | Astley-Sparke Philip Chief Executive Officer | 355,250 | $0 | 1,756,330 (Direct) | View |
| 2022-04-01 Option Award | 2022-04-05 4:18 pm | N/A 2032-04-01 | Replimune Group Inc. | REPL | Astley-Sparke Philip Chief Executive Officer | 175,000 | $0 | 1,515,712 (Direct) | View |